Vice President, Program Management, and Asset Strategy
Jean Chang has served as Vice President, Program Management, and Asset Strategy since 2019. Prior to joining Nurix, she was Oncology Project Lead and Vice President Corporate Development at Dynavax Technologies. In this role she was responsible for strategic leadership for the company’s immuno-oncology pipeline and for identifying and accessing technologies to advance its oncology programs, including establishing and managing key clinical stage collaborations with pharmaceutical partners. Jean has led marketing and new product planning for therapeutics in various disease areas including central nervous system, HIV, hepatitis B, rare diseases, and autoimmune diseases and was instrumental in the successful commercial launches of Hepsera®, Ceredase®, Cerezyme® and Savella®. She previously worked at Gilead Sciences, Chiron, Cypress Bioscience, Corgentech, and Anesiva, and led European marketing and global commercial operations for Genzyme. She received her A.B. in biology from Smith College.